Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will participate in a fireside chat at the H.C.

Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York. The session is scheduled for Monday, September 14, 2026, at 2:00 PM ET, with a live webcast and 90-day replay available via Elicio’s Events page. Interested attendees can request 1×1 meetings with management through their H.C. Wainwright representative.

Argus Aug 31 session 5 alerts

-4.93% close to close 2.0x rel. volume Open Argus

Details

Market move: ELTX -4.93% in the Aug 31 session. conference participation

$71.49M Market Cap

On Aug 31, the day this news came out, ELTX closed 4.93% below the previous close. Our momentum scanner recorded 5 alerts for this stock that day. Relative volume reached 2.0x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 31 session.

Key Figures

Announcement Date: August 31, 2026 Conference Dates: September 14-16, 2026 Fireside Chat Date: September 14, 2026 +4 more

Announcement Date

August 31, 2026

News publication date

Conference Dates

September 14-16, 2026

H.C. Wainwright 28th Annual Global Investment Conference

Fireside Chat Date

September 14, 2026

Scheduled company presentation

Presentation Time

2:00 PM ET

Scheduled fireside chat

Replay Availability

90 days

Webcast replay availability following the event

One-on-One Meetings

1×1

Meeting format available at the conference

Conference Edition

28th Annual

H.C. Wainwright Global Investment Conference

Historical Context

5 past events · Latest: Aug 24

5 events

1. Aug 24

   Conference participation

   24h Move

   -2.0%

   Management announced one-on-one meetings at the Wells Fargo healthcare conference.

2. Aug 13

   Second-quarter earnings

   24h Move

   -1.9%

   Phase 2 trial missed its primary endpoint despite additional clinical updates.

3. Aug 10

   Phase 1 trial activation

   24h Move

   -2.8%

   Investigator-initiated neoadjuvant study of ELI-002 7P was activated.

4. Jul 06

   Registered direct offering

   24h Move

   -15.0%

   Registered direct offering closed with approximately $15 million in gross proceeds.

5. Jul 02

   Offering pricing

   24h Move

   -37.4%

   Company priced a registered direct offering of 4,380,313 common shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.

H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat
Date: Monday, September 14, 2026
Time: 2:00 PM ET

The live webcast and replay of the presentation will be available here and on Elicio’s Events page for 90 days following the event.

If you are interested in arranging a 1×1 meeting with management at the conference, please contact your H.C. Wainwright representative.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation, and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing, and rapid availability of drug to patients, especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Elicio Therapeutics (NASDAQ: ELTX) present at the H.C. Wainwright 28th Annual Global Investment Conference?

Elicio Therapeutics will participate in a fireside chat on Monday, September 14, 2026, at 2:00 PM ET. According to Elicio Therapeutics, this session is part of the H.C. Wainwright 28th Annual Global Investment Conference in New York, running from September 14-16, 2026.

Who will represent Elicio Therapeutics (ELTX) at the H.C. Wainwright 2026 Global Investment Conference?

Elicio Therapeutics will be represented by CEO Robert Connelly and CSO Pete DeMuth, PhD. According to Elicio Therapeutics, they will participate together in a fireside chat session during the H.C. Wainwright 28th Annual Global Investment Conference in New York.

How can investors watch Elicio Therapeutics’ ELTX fireside chat at the H.C. Wainwright conference?

Investors can watch a live webcast of Elicio Therapeutics’ fireside chat and access a replay. According to Elicio Therapeutics, the webcast link will be available on the company’s Events page and remain accessible for 90 days following the conference session.

Can investors schedule 1x1 meetings with Elicio Therapeutics (ELTX) management at the H.C. Wainwright 2026 conference?

Yes, investors can request 1×1 meetings with Elicio Therapeutics’ management during the conference. According to Elicio Therapeutics, interested parties should contact their H.C. Wainwright representative to arrange individual meetings around the time of the fireside chat.

What type of session will Elicio Therapeutics hold at the H.C. Wainwright 28th Annual Global Investment Conference?

Elicio Therapeutics will participate in a fireside chat format session at the conference. According to Elicio Therapeutics, this discussion-style presentation, featuring the CEO and CSO, is scheduled for September 14, 2026, at 2:00 PM ET in New York.